The Wall Street Journal reported on Wednesday that India is in talks to buy 50 million doses of Pfizer Inc’s COVID-19 vaccine from German partner BioNTech SE, citing people familiar with the subject.

Pfizer and the Indian Ministry of Health did not immediately respond to a request for comment from Reuters. The pharmaceutical company has not yet applied for approval to use its vaccine in India.

The country, which rolled out one of the world’s largest vaccination drives earlier this year, has been relying heavily on the AstraZeneca vaccine produced by the Serum Institute of India and a home-grown shot produced by Bharat Biotech.

Authorities are also in an advanced stage of negotiations with Johnson & Johnson, which has a deal with India-based Biological E. Ltd, to manufacture as many as 600 million doses, starting as soon as this month, the Journal reported.

Last week, the country approved J&J’s one-shot vaccine for emergency use, adding to the vaccines from AstraZeneca, Bharat Biotech, Russia’s Gamaleya Institute and Moderna, that have been granted such approval.